SOURCE: Stem Cell Therapy International, Inc.

July 17, 2007 09:00 ET

Stem Cell Therapy International, Inc. Reports 327% Increase in Revenue

TAMPA, FL--(Marketwire - July 17, 2007) - Stem Cell Therapy International, Inc. (OTCBB: SCII) announced today that as reported in its 10KSB filing for the reporting period ending March 31, 2007 that it has increased revenues by 327% from its expanding stem cell treatment services over the comparable period in 2006. Calvin Cao, CEO of SCII.OB, went on to state, "Not only have we been able to increase revenues, but we have eliminated a significant cost of goods that will now save the company $120,000 per year over what had been paid in the past. We are very encouraged by our progress so far and look forward to exploring the numerous opportunities we have available for continued growth and expansion."


As of March 31, 2007 and for the years March 31, 2007 and 2006. We had revenue of $345,510 during the year ended March 31, 2007 as compared to $80,934 of revenue for the comparable period in 2006. Revenues during 2007 reflected the treatment of nine patients and only three patients were treated during the same period ended 2006. Our cost of goods sold for the stem cell biological material delivered during the year ended March 31, 2007 was $289,993 as compared to $52,100 for the same period ended 2006. Gross margin for the year ended March 31, 2007 was $55,517 as compared to $28,834 for the year ended March 31, 2006. Gross margin as a percentage of revenue for the year ended March 31, 2007 was 16% as compared to 36% for the year ended March 31, 2006. The decreased gross margin is primarily due to the additional $116,000 charge by ICT for not meeting the minimum purchase requirements.

About Stem Cell Therapy International

Stem Cell Therapy International, Inc. is engaged in the field of regenerative medicine. This includes ongoing research, development and the use of stem cell transplantation therapy for those suffering from degenerative disorders such as Alzheimer's, Parkinson's disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver failure, retinal disease and diabetes. The company has established affiliate agreements with highly specialized, professional medical treatment facilities in various worldwide locations where stem cell transplantation therapy by licensed physicians is approved for patient use in those jurisdictions. With its leading edge treatment clinics in countries now allowing stem cell treatments, and thus generating current revenues, the company also plans to gain a presence in the U.S. market, as an additional revenue source, as soon as stem cell procedures are approved by the FDA. For further information visit the company's website

Forward-Looking Statements. This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct.

Contact Information

  • For more information, please contact:
    Stem Cell Therapy International, Inc.

    Investor Relations:
    Mirador Consulting Inc.
    Frank Beneddeto
    T: 561-989-3600

    New Clinic Partners, Licensing and Joint Ventures:
    Gerald R. Newman, Esq.
    T: 310-652-6642

    Calvin Cao
    Chairman and CEO
    T: 813-600-4088